Corticosteroids in Sepsis: An Updated Systematic Review and Meta-Analysis

Critical Care Medicine

Volumn 46, Issue 9, 2018, Pages 1411-1420

  Rochwerg, Bram ^a   Oczkowski, Simon J ^a   Siemieniuk, Reed A C ^a   Agoritsas, Thomas ^a,b   Belley Cote, Emilie ^a   D'Aragon, Frédérick ^c   Duan, Erick ^a   English, Shane ^d,e   Gossack Keenan, Kira ^a   Alghuroba, Mashari ^a   Szczeklik, Wojciech ^a,f   Menon, Kusum ^d   Alhazzani, Waleed ^a   Sevransky, Jonathan ^g   Vandvik, Per Olav ^h   Annane, Djillali ⁱ   Guyatt, Gordon ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE   (Canada)

^d UNIVERSITY OF OTTAWA   (Canada)

^e OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^f JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^g EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h INNLANDET HOSPITAL TRUST   (Norway)

ⁱ LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

Author keywords

Corticosteroids; Immune response; Meta analysis; Sepsis; Systematic review

Indexed keywords

CORTICOSTEROID; HYDROCORTISONE;

ARTICLE; CEREBROVASCULAR ACCIDENT; CRITICALLY ILL PATIENT; DYING; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HUMAN; HYPERGLYCEMIA; HYPERNATREMIA; INTENSIVE CARE UNIT; LENGTH OF STAY; META ANALYSIS; MORTALITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; RISK REDUCTION; SEPSIS; SEQUENTIAL ORGAN FAILURE ASSESSMENT SCORE; SUPERINFECTION; SYSTEMATIC REVIEW; CRITICAL ILLNESS; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; CRITICAL ILLNESS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEPSIS; TREATMENT OUTCOME;

EID: 85051433688     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0000000000003262     Document Type: Article

References (62)

1. Seymour CW, Liu VX, Iwashyna TJ, et al: Assessment of clinical criteria for sepsis: For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 2016;315:762-774
2. Rhee C, Dantes R, Epstein L, et al; CDC Prevention Epicenter Program: Incidence and trends of sepsis in US hospitals using clinical vs claims data, 2009-2014. JAMA 2017;318:1241-1249
3. Rhodes A, Evans LE, Alhazzani W, et al: Surviving sepsis campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Intensive Care Med 2017;43:304-377
4. Shankar-Hari M, Phillips GS, Levy ML, et al; Sepsis Definitions Task Force: Developing a new definition and assessing new clinical criteria for septic shock: For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 2016;315:775-787
5. Annane D, Pastores SM, Arlt W, et al: Critical illness-related corticosteroid insufficiency (CIRCI): A narrative review from a Multispecialty Task Force of the Society of Critical Care Medicine (SCCM) and the European Society of Intensive Care Medicine (ESICM). Intensive Care Med 2017;43:1781-1792
6. Annane D, Bellissant E, Bollaert PE, et al: Corticosteroids for treating sepsis. Cochrane Database Syst Rev 2015; (12):CD002243
7. Volbeda M, Wetterslev J, Gluud C, et al: Glucocorticosteroids for sepsis: Systematic review with meta-analysis and trial sequential analysis. Intensive Care Med 2015;41:1220-1234
8. Keh D, Trips E, Marx G, et al; SepNet-Critical Care Trials Group: Effect of hydrocortisone on development of shock among patients with severe sepsis: The HYPRESS randomized clinical trial. JAMA 2016;316:1775-1785
9. Gordon AC, Mason AJ, Thirunavukkarasu N, et al; VANISH Investigators: Effect of early vasopressin vs norepinephrine on kidney failure in patients with septic shock: The VANISH randomized clinical trial. JAMA 2016;316:509-518
10. Siemieniuk RA, Agoritsas T, Macdonald H, et al: Introduction to BMJ Rapid Recommendations. BMJ 2016;354:i5191
11. Venkatesh B, Finfer S, Cohen J, et al: Adjunctive glucocorticoid therapy in patients with septic shock. N Engl J Med 2018;378:797-808
12. Annane D, Renault A, Brun-Buisson C, et al; CRICS-TRIGGERSEP Network: Hydrocortisone plus fludrocortisone for adults with septic shock. N Engl J Med 2018;378:809-818
13. Rochwerg B, Oczkowski S, Siemieniuk RA, et al: Corticosteroids in sepsis: An updated systematic review and meta-analysis (protocol). BMJ Open 2017;7:e016847
14. Guyatt GH, Oxman AD, Kunz R, et al: GRADE guidelines:2. Framing the question and deciding on important outcomes. J Clin Epidemiol 2011;64:395-400
15. Levy MM, Fink MP, Marshall JC, et al: 2001 SCCM/ESICM/ACCP/ ATS/SIS International Sepsis Definitions Conference. Critical Care Med 2003;31:1250-1256
16. Singer M, Deutschman CS, Seymour CW, et al: The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 2016;315:801-810
17. Bone RC, Balk RA, Cerra FB, et al: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992;101:1644-1655
18. Minne L, Abu-Hanna A, de Jonge E: Evaluation of SOFA-based models for predicting mortality in the ICU: A systematic review. Crit Care 2008;12:R161
19. Guyatt GH, Busse J: Evidence Partners. 2013. Available at: http:// distillercer.com/resources/methodological-resources/risk-of-biascommentary/. Accessed September 6, 2013
20. Guyatt GH, Oxman AD, Vist GE, et al: GRADE: An emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336:924-926
21. Higgins JP, Altman DG, Gotzsche PC, et al: The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928
22. Sun X, Briel M, Busse JW, et al: Credibility of claims of subgroup effects in randomised controlled trials: Systematic review. BMJ 2012;344:e1553
23. The Veterans Administration Systemic Sepsis Cooperative Study Group: Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. N Eng J Med 1987;317:659-665
24. Annane D, Sébille V, Charpentier C, et al: Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002;288:862-871
25. Arabi YM, Aljumah A, Dabbagh O, et al: Low-dose hydrocortisone in patients with cirrhosis and septic shock: A randomized controlled trial. CMAJ 2010;182:1971-1977
26. Bollaert PE, Charpentier C, Levy B, et al: Reversal of late septic shock with supraphysiologic doses of hydrocortisone. Crit Care Med 1998;26:645-650
27. Bone RC, Fisher CJ Jr, Clemmer TP, et al: A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 1987;317:653-658
28. Briegel J, Forst H, Haller M, et al: Stress doses of hydrocortisone reverse hyperdynamic septic shock: A prospective, randomized, double-blind, single-center study. Crit Care Med 1999;27:723-732
29. Chawla K, Kupfer Y, Goldman I, et al: Hydrocortisone reverses refractory septic shock. Crit Care Med 1999;27:Supplement page 33A
30. Cicarelli DD, Vieira JE, Benseñor FE: Early dexamethasone treatment for septic shock patients: A prospective randomized clinical trial. Sao Paulo Med J 2007;125:237-241
31. Confalonieri M, Urbino R, Potena A, et al: Hydrocortisone infusion for severe community-acquired pneumonia: A preliminary randomized study. Am J Respir Crit Care Med 2005;171:242-248
32. Gordon AC, Mason AJ, Perkins GD, et al: The interaction of vasopressin and corticosteroids in septic shock: A pilot randomized controlled trial. Crit Care Med 2014;42:1325-1333
33. Group CS: The effectiveness of hydrocortisone in the management of severe infections. JAMA 1963;183:462-465
34. Hu B, Li JG, Liang H, et al: The effect of low-dose hydrocortisone on requirement of norepinephrine and lactate clearance in patients with refractory septic shock. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue 2009;21:529-531
35. Liu L, Li J, Huang YZ, et al: The effect of stress dose glucocorticoid on patients with acute respiratory distress syndrome combined with critical illness-related corticosteroid insufficiency. Zhonghua Nei Ke Za Zhi 2012;51:599-603
36. Luce JM, Montgomery AB, Marks JD, et al: Ineffectiveness of highdose methylprednisolone in preventing parenchymal lung injury and improving mortality in patients with septic shock. Am Rev Respir Dis 1988;138:62-68
37. Meduri GU, Golden E, Freire AX, et al: Methylprednisolone infusion in early severe ARDS: Results of a randomized controlled trial. Chest 2007;131:954-963
38. Meijvis SC, Hardeman H, Remmelts HH, et al: Dexamethasone and length of hospital stay in patients with community-acquired pneumonia: A randomised, double-blind, placebo-controlled trial. Lancet 2011;377:2023-2030
39. Oppert M, Schindler R, Husung C, et al: Low-dose hydrocortisone improves shock reversal and reduces cytokine levels in early hyperdynamic septic shock. Crit Care Med 2005;33:2457-2464
40. Rezk N, Ibrahim A: Effects of methylprednisolone in early ARDS. Egypt J Chest Dis Tuberc 2013;62:167-172
41. Rinaldi S, Adembri C, Grechi S, et al: Low-dose hydrocortisone during severe sepsis: Effects on microalbuminuria. Crit Care Med 2006;34:2334-2339
42. Sabry N, Omar EED: Corticosteroids and ICU course of community acquired pneumonia in Egyptian settings. Pharmacol Pharm 2011;2:73-81
43. Schumer W: Steroids in the treatment of clinical septic shock. Ann Surg 1976;184:333-341
44. Slusher T, Gbadero D, Howard C, et al: Randomized, placebo-controlled, double blinded trial of dexamethasone in African children with sepsis. Pediatr Infect Dis J 1996;15:579-583
45. Snijders D, Daniels JM, de Graaff CS, et al: Efficacy of corticosteroids in community-acquired pneumonia: A randomized double-blinded clinical trial. Am J Respir Crit Care Med 2010;181:975-982
46. Sprung CL, Annane D, Keh D, et al; CORTICUS Study Group: Hydrocortisone therapy for patients with septic shock. N Engl J Med 2008;358:111-124
47. Sprung CL, Caralis PV, Marcial EH, et al: The effects of high-dose corticosteroids in patients with septic shock. A prospective, controlled study. N Engl J Med 1984;311:1137-1143
48. Tandan SM, Guleria R, Gupta N: Low dose steroids and adrenocortical insufficiency in septic shock: A double-blind randomized controlled trial from India. In: Proceedings of the American Thoracic Society Meeting, New York, NY, 2005:A24
49. Torres A, Sibila O, Ferrer M, et al: Effect of corticosteroids on treatment failure among hospitalized patients with severe communityacquired pneumonia and high inflammatory response: A randomized clinical trial. JAMA 2015;313:677-686
50. Valoor HT, Singhi S, Jayashree M: Low-dose hydrocortisone in pediatric septic shock: An exploratory study in a third world setting. Pediatr Crit Care Med 2009;10:121-125
51. Yildiz O, Doganay M, Aygen B, et al: Physiological-dose steroid therapy in sepsis [ISRCTN36253388]. Crit Care 2002;6:251-259
52. Yildiz O, Tanriverdi F, Simsek S, et al: The effects of moderate-dose steroid therapy in sepsis: A placebo-controlled, randomized study. J Res Med Sci 2011;16:1410-1421
53. Branco RG, Amoretti CF, Garcia PCR, et al: Corticosteroid replacement in sepsis induces lymphopenia: Results of a randomized controlled trial. Pediatr Crit Care Med 2014;15(4 Suppl):12
54. De Graaf H, Ramakrishnan KA, Pappachan J, et al: Evaluation of corticosteroid replacement therapy in children with severe septic shock - a randomised intervention trial. Pediatr Crit Care Med 2014;15(4 Suppl):141
55. El-Nawawy A, Khater D, Omar H, et al: Evaluation of early corticosteroid therapy in management of pediatric septic shock in pediatric intensive care patients: A randomized clinical study. Pediatr Infect Dis J 2017;36:155-159
56. Lv QQ, Gu XH, Chen QH, et al: Early initiation of low-dose hydrocortisone treatment for septic shock in adults: A randomized clinical trial. Am J Emerg Med 2017;35:1810-1814
57. Menon K, McNally D, O'Hearn K, et al; Canadian Critical Care Trials Group: A randomized controlled trial of corticosteroids in pediatric septic shock: A pilot feasibility study. Pediatr Crit Care Med 2017;18:505-512
58. Mirea L, Ungureanu R, Pavelescu D, et al: Continuous administration of corticosteroids in septic shock can reduce risk of hypernatremia. Crit Care 2014;18(Suppl 1):P239
59. Tongyoo S, Permpikul C, Mongkolpun W, et al: Hydrocortisone treatment in early sepsis-associated acute respiratory distress syndrome: Results of a randomized controlled trial. Crit Care 2016;20:329
60. Meduri G, Golden E, Freire A, et al: Randomized clinical trial evaluating the effects of low-dose prolonged hydrocortisone infusion on resolution of MODS in severe sepsis. Chest 2009;136(Suppl):154
61. Gibbison B, López-López JA, Higgins JP, et al: Corticosteroids in septic shock: A systematic review and network meta-analysis. Crit Care 2017;21:78
62. Oray M, Abu Samra K, Ebrahimiadib N, et al: Long-term side effects of glucocorticoids. Expert Opin Drug Saf 2016;15:457-465